key: cord-0841922-ugnjj3xf
authors: Etaee, Farshid; Ghanei, Narges; Naguib, Tarek; Daveluy, Steven
title: Acute generalized exanthematous pustulosis: a complication of COVID‐19 infection or therapy?
date: 2022-04-05
journal: J Cosmet Dermatol
DOI: 10.1111/jocd.14930
sha: 92f02151bf81cf9417dca337faaa80777770d7c0
doc_id: 841922
cord_uid: ugnjj3xf

nan

mycin 500 mg once daily and hydroxychloroquine (HCQ) 400 mg orally twice daily on the first day, then 400 mg once daily for the next 4 days. Six days after the completion of the treatment, the patient developed a pruritic rash on her face and neck. Over the next 5 days, she developed widespread erythema, scaling, and pustules covering more than half of her body surface area. She had prominent facial and trunk involvement with no mucosal involvement ( Figure 1 ). She had fever (38.1°C), chills, and generalized aches.

White blood cell count was 22 700/μL with a left shift and no eosinophilia. Blood cultures were negative. ESR was 35 mm/h. She had no personal or family history of skin diseases. Biopsy revealed intraepidermal and subcorneal collections of neutrophils with no parakeratosis, consistent with a diagnosis of AGEP. Eosinophil infiltration was seen within the superficial dermis. Culture from pustules grew no bacteria. Intravenous methylprednisolone, oral famotidine, and oral hydroxyzine were initiated. Intravenous vancomycin was administered empirically until cultures returned. On the third day, the methylprednisolone was changed to oral prednisone 50 mg daily, and the edema, erythema, and pustules began to resolve. She was discharged on a tapering dose of oral prednisone, and the rash resolved after 4 weeks.

We found 13 articles that reported 24 cases of AGEP in patients with COVID-19 infection, with 14 males (58%). The details of these manuscripts are summarized in Table 1 after COVID-19 infection that was treated with azithromycin. It is unclear whether the AGEP was related to COVID-19 infection and/or azithromycin. 3 The onset of AGEP following COVID-19 diagnosis/treatment was ranging from 3 days to 3 months. Two out of 24 cases died due to pulmonary thromboembolism 4, 5 ; no one died due to COVID-19 pneumonia alone. One of these two patients developed acute respiratory distress syndrome requiring invasive mechanical ventilation. 4

In reviewing all cases, we found no reports of AGEP in the setting of COVID-19 in patients who were not receiving drug therapy.

It appears that AGEP can be a 

Not declared.

The authors declare that no ethical approval was needed for this manuscript.

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

Delayed presentation of acute generalized exanthematous pustulosis following treatment with cefepime in a patient with COVID-19 without the use of hydroxychloroquine

A case of cefditoren-induced acute generalized exanthematous pustulosis during COVID-19 pandemics. Severe cutaneous adverse reactions are an issue

Late-onset AGEP-like skin pustular eruption following COVID-19: a possible association

Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19

Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine

A rare skin complication of hydroxychloroquine therapy for positive coronavirus disease 2019 infection: acute generalized exanthematous pustulosis

Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19)

Acute generalized exanthematous pustulosis after COVID-19 infection: a case report from Saudi Arabia

Hydroxychloroquine-induced acute generalized exanthematous pustulosis: an adverse reaction to keep in mind during COVID-19 pandemic

International of academic medicine and pharmacy

Cutaneous eruption in COVID-19-infected patients in Thailand: an observational descriptive study

Acute generalized exanthematous pustulosis (AGEP) in 12 patients treated for SARS-CoV-2 positive pneumonia

Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test